Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.
Robert Coleman, MD, FACOG, FACS, chief scientific officer for US Oncology Research, supported by McKesson, and an oncologist with Texas Oncology, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented during the Association of Community Cancer Centers (ACCC) Annual Meeting.
In lung cancer, there is always a need for research, says Coleman. But there are certain subgroups for which oncologists need more information to provide optimal care. This data will likely come from real-world research rather than clinical trial research. This is mainly because of the restrictive eligibility criteria of some clinical trials.
The presence of comorbidities, age, performance status, and other factors play a role in how patients respond to therapy, Coleman notes. With real-world research through programs like MyLung and others, the lung cancer field has a better chance of understanding how best to treat the various subgroups of patients.